Sartorius Stedim Biotech (OTCMKTS:SDMHF) Trading 5.5% Higher – What’s Next?

Sartorius Stedim Biotech S.A. (OTCMKTS:SDMHF) traded up 5.5% on Friday . The stock traded as high as $229.00 and last traded at $229.00. 90 shares were traded during mid-day trading, a decline of 96% from the average session volume of 2,051 shares. The stock had previously closed at $217.09.

Analysts Set New Price Targets

Separately, UBS Group upgraded Sartorius Stedim Biotech to a “buy” rating in a research note on Thursday, August 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Sartorius Stedim Biotech presently has an average rating of “Moderate Buy”.

Sartorius Stedim Biotech Stock Performance

The business’s 50-day moving average price is $204.97 and its 200 day moving average price is $201.72.

Sartorius Stedim Biotech Company Profile

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems.